Company Profile
Adaptimmune Therapeutics plc Stock Price, News & Analysis
- Ticker:
- ADAP
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom
Why the stock is moving
Current closing-price context is not available for ADAP.
Company overview
Business overview
Adaptimmune Therapeutics is a cell-therapy company focused on engineered T-cell therapies for cancer. Its platform aims to make T-cell treatment more precise and scalable.
Geographic Base and Sector Classification
Headquartered in the United Kingdom and listed on NASDAQ as an ADR, Adaptimmune has a global cell-therapy profile.
Business Model Characteristics
The company depends on clinical validation, manufacturing execution, and the ability to commercialize engineered cell therapy.
Position Within the Biotechnology Landscape
Adaptimmune is a high-catalyst cell-therapy name whose valuation depends on clinical and launch progress.
Future catalysts
Adaptimmune’s catalysts are Tecelra commercialization and the broader engineered T-cell platform, including lete-cel. The key issue is whether the company can keep turning a cell-therapy platform into an actual commercial franchise.
Recent news
- 01
Adaptimmune Announces Changes to Board and Executive Leadership Team
Source: Adaptimmune Therapeutics plc
- 02
Adaptimmune Announces Delisting from Nasdaq
Source: Adaptimmune Therapeutics plc
- 03
Adaptimmune Reports Q2 Financial Results and Provides Business Update
Source: Adaptimmune Therapeutics plc
- 04
Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds
Source: Adaptimmune Therapeutics plc
- 05
Adaptimmune Reports Q1 Financial Results and Provides Business Update
Source: Adaptimmune Therapeutics plc
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Adaptimmune Therapeutics plc do?
Adaptimmune Therapeutics is a cell-therapy company focused on engineered T-cell therapies for cancer. Its platform aims to make T-cell treatment more precise and scalable.
On which exchange is ADAP stock listed?
Adaptimmune Therapeutics plc (ADAP) is associated with NASDAQ, United Kingdom, Biopharma.
What is Adaptimmune?
Adaptimmune’s catalysts are Tecelra commercialization and the broader engineered T-cell platform, including lete-cel.
Which conditions is Adaptimmune Therapeutics plc targeting with Adaptimmune?
Adaptimmune Therapeutics plc is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Adaptimmune Therapeutics plc describe recent progress with Adaptimmune?
Adaptimmune’s catalysts are Tecelra commercialization and the broader engineered T-cell platform, including lete-cel.
What is Therapeutics?
Adaptimmune Therapeutics is a cell-therapy company focused on engineered T-cell therapies for cancer.
What should investors watch for with Therapeutics?
Adaptimmune’s catalysts are Tecelra commercialization and the broader engineered T-cell platform, including lete-cel. The key issue is whether the company can keep turning a cell-therapy platform into an actual commercial franchise.
What is T-cell?
Adaptimmune Therapeutics is a cell-therapy company focused on engineered T-cell therapies for cancer.